antivir
antibodi
constitut
import
compon
host
immun
respons
viral
infect
serv
neutral
reduc
infect
viru
howev
antibodi
intend
protect
host
may
sometim
prove
benefici
viru
facilit
viral
entri
replic
target
cell
phenomenon
known
antibodydepend
enhanc
ade
infect
result
interact
virusantibodi
immun
complex
andor
complement
receptor
certain
type
host
cell
promot
viral
entri
host
cell
intern
immun
complex
modul
host
immun
respons
enhanc
viral
replic
aggrav
diseas
sever
possibl
induct
ade
remain
concern
develop
implement
viral
vaccin
immunotherapeut
antibodydepend
enhanc
ade
infect
repres
paradox
phenomenon
hostpathogen
biolog
antibodi
import
pillar
host
defens
invad
pathogen
actual
allow
entri
pathogen
host
territori
traitor
behavior
antibodi
serv
weaken
host
defens
system
thu
gener
environ
conduc
enhanc
growth
pathogen
consequ
exacerb
diseas
host
phenomenon
farreach
implic
diseas
control
prevent
therapeut
antibodi
deploy
protect
host
may
aid
pathogen
instead
similarli
antibodi
induc
vaccin
may
actual
increas
risk
andor
sever
diseas
subsequ
hostpathogen
encount
chapter
aim
provid
insight
current
knowledg
ade
viral
infect
focu
molecular
mechan
contribut
viral
pathogenesi
diseas
well
implic
diseas
control
strategi
antibodi
import
compon
host
adapt
immun
respons
infect
viru
viru
neutral
consid
key
mechan
antibodymedi
protect
antivir
activ
antibodi
augment
fcmediat
effector
mechan
complementmedi
lysi
viral
particl
phagocytosi
antibodydepend
cellular
cytotox
adcc
bracial
et
al
neutral
occur
antibodi
molecul
bind
viru
particl
surfac
epitop
block
viral
attach
cellular
receptor
entri
host
cell
andor
postentri
process
fusion
uncoat
thu
result
loss
virion
infect
fig
two
model
propos
describ
kinet
neutral
accord
singlehit
model
bind
singl
antibodi
molecul
critic
site
virion
suffici
neutral
accept
multihit
model
postul
neutral
achiev
virion
bound
multipl
antibodi
exceed
stoichiometr
threshold
neutral
klass
sattentau
potenc
neutral
determin
affin
antibodi
bind
access
neutral
epitop
viral
surfac
dowd
et
al
phenomenon
antibodydepend
enhanc
ade
discov
flavivirus
observ
studi
dengu
viru
denv
infect
reveal
signific
associ
sever
ill
antibodi
respons
secondari
infect
halstead
et
al
vitro
experi
demonstr
increas
infect
murray
valley
enceph
viru
hawk
hawk
lafferti
denv
halstead
et
al
presenc
antibodi
vivo
studi
rhesu
monkey
show
associ
antibodi
respons
higher
dengu
viremia
offer
support
evid
phenomenon
halstead
et
al
halstead
marchett
et
al
ade
ensu
antibodi
bind
viru
particl
fail
effici
neutral
viru
halstead
taylor
et
al
may
occur
due
nonneutr
natur
antibodi
bind
viral
epitop
involv
cell
attach
entri
presenc
subneutr
concentr
antibodi
bind
viral
epitop
threshold
neutral
either
way
antibodi
aid
entri
viru
target
cell
result
enhanc
viral
infect
known
antibodydepend
enhanc
fig
mechan
ade
involv
intern
virusantibodi
immun
complex
cell
via
interact
antibodi
fc
region
cellular
fc
receptor
fcr
consequ
fcrbear
myeloid
cell
monocyt
macrophag
dendrit
cell
certain
granulocyt
permiss
ade
infect
phagocyt
uptak
immun
complex
ade
princip
mediat
igg
antibodi
howev
igm
along
complement
iga
antibodi
also
shown
capabl
ade
hawk
lafferti
cardosa
et
al
janoff
et
al
kozlowski
et
al
initi
role
antibodi
enhanc
viral
infect
believ
limit
facilit
viru
entri
host
cell
result
increas
number
infect
cell
consequ
higher
viru
product
process
term
extrins
ade
howev
studi
ross
river
viru
suggest
intern
immun
complex
serv
enhanc
viral
replic
suppress
cellular
innat
antivir
immun
respons
lidburi
mahalingam
suhrbier
la
linn
mechan
term
intrins
ade
subsequ
observ
flavivirus
well
chareonsirisuthigul
et
al
ubol
et
al
thu
ade
complex
phenomenon
compris
extrins
intrins
compon
togeth
contribut
augment
viral
infect
replic
consequ
increas
viru
product
massiv
releas
inflammatori
vasoact
mediat
host
cell
ultim
lead
exacerb
viral
pathogenesi
diseas
sever
prior
sensit
humor
immun
respons
prerequisit
ade
halstead
taylor
et
al
phenomenon
thu
wide
observ
secondari
infect
heterotyp
viru
genu
wherein
preexist
antibodi
primari
sensit
infect
bind
secondari
viru
fail
neutral
pathogen
outcom
secondari
infect
influenc
time
interv
primarysecondari
infect
increas
time
associ
sever
diseas
may
explain
wane
broadli
neutral
antibodi
time
passiv
acquir
antibodi
also
capabl
induc
ade
indic
enhanc
viral
diseas
preexist
matern
antibodi
infant
born
dengueimmun
mother
klik
et
al
chau
et
al
chau
et
al
ade
phenomenon
implic
use
antivir
immunoglobulin
therapi
viral
infect
due
associ
risk
enhanc
diseas
taylor
et
al
ade
also
pose
major
challeng
implement
vaccin
program
vaccineinduc
antibodi
may
enhanc
subsequ
viral
infect
thu
place
vaccin
recipi
increas
risk
sever
diseas
inde
concern
regard
safeti
world
first
licens
dengu
vaccin
dengvaxia
forc
author
reconsid
mass
vaccin
strategi
issu
specif
recommend
safe
implement
vaccin
dengu
control
program
wildersmith
et
al
ade
exploit
varieti
virus
belong
differ
viru
famili
mechan
clinic
signific
ade
select
virus
review
chapter
also
summar
tabl
ade
phenomenon
extens
studi
dengu
viru
consid
detail
dengu
viru
denv
member
famili
flavivirida
genu
flaviviru
transmit
human
bite
aed
mosquito
mainli
aed
aegypti
infect
four
serotyp
viru
may
asymptomat
lead
dengu
fever
symptom
rang
mild
highdegre
fever
headach
myalgia
arthralgia
rash
retroorbit
pain
patient
ill
may
progress
lifethreaten
sever
dengu
earlier
classifi
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
character
increas
vascular
permeabl
plasma
leakag
extens
pleural
effus
sever
hemorrhag
respiratori
distress
organ
failur
dengu
diseas
endem
countri
consid
major
public
health
problem
worldwid
estim
million
case
death
report
annual
bhatt
et
al
absenc
effect
antivir
dengu
treatment
mainli
reli
symptomat
intervent
though
licens
vaccin
avail
implement
mass
immun
program
remain
complic
due
ade
discuss
later
section
denv
genom
singlestrand
positivesens
rna
molecul
kb
size
contain
singl
open
read
frame
code
larg
polyprotein
subsequ
process
three
structur
protein
capsid
c
membran
envelop
e
least
seven
nonstructur
protein
lindenbach
et
al
e
glycoprotein
major
surfaceexpos
region
viru
display
viral
antigen
determin
function
bind
cellular
receptor
fuse
host
cell
membran
viru
penetr
also
direct
viral
assembl
bud
e
protein
monom
divid
three
structuralfunct
domainsedi
central
region
edii
site
fusion
ediii
site
receptor
bind
modi
et
al
protein
initi
express
membran
precursor
prm
present
intracellular
immatur
viru
particl
virion
assembl
matur
involv
cleavag
precursor
pr
peptid
result
releas
matur
viru
particl
contain
protein
extracellular
environ
li
et
al
junjhon
et
al
possibl
immun
enhanc
denv
infect
first
suggest
observ
strong
associ
sever
diseas
dhfdss
secondari
infect
among
dengu
patient
bangkok
thailand
halstead
et
al
guzman
et
al
initi
find
support
prospect
seroepidemiolog
studi
show
higher
rate
dhfdss
secondari
infect
sangkawibha
et
al
graham
et
al
halstead
associ
secondari
heterotyp
denv
differ
serotyp
infect
ade
sever
dengu
strengthen
report
dhfdss
case
cuba
outbreak
denv
outbreak
popul
immun
respect
guzman
et
al
guzman
et
al
alvarez
et
al
demonstr
secondari
dhfdss
case
higher
viremia
level
proinflammatori
cytokin
suggest
greater
infect
cell
mass
subsequ
increas
cytokin
releas
contribut
diseas
sever
patient
vaughn
et
al
wang
et
al
rothman
howev
interestingli
tertiaryquaternari
denv
infect
rare
associ
sever
diseas
presum
due
suffici
crossprotect
immun
acquir
two
primarysecondari
differ
denv
infect
gibbon
et
al
compel
evid
ade
provid
observ
sever
dengu
primari
infect
infant
born
dengueimmun
mother
klik
et
al
chau
et
al
chau
et
al
first
month
birth
passiv
acquir
matern
antibodi
shown
protect
infant
symptomat
dengu
thereaft
matern
antibodi
begin
declin
reach
subneutr
level
antibodi
capabl
enhanc
denv
infect
enhanc
antibodi
persist
till
month
age
place
infant
increas
risk
sever
dengu
inde
enhanc
activ
infant
sera
demonstr
vitro
denvad
support
extens
vitro
experi
enhanc
denv
infect
antidenv
monoclon
antibodi
polyclon
human
immun
sera
observ
primari
human
myeloid
cell
well
cell
line
cell
monocyt
cell
macrophagelik
cell
halstead
et
al
moren
et
al
cardosa
klik
goncalvez
et
al
moi
et
al
guzman
et
al
acosta
bartenschlag
moreov
vitro
ade
human
sera
associ
sever
dengu
patient
ade
phenomenon
also
demonstr
anim
studi
higher
viremia
record
experiment
secondari
infect
rhesu
monkey
well
passiv
immun
monkey
halstead
et
al
halstead
marchett
et
al
goncalvez
et
al
denvspecif
antibodi
shown
enhanc
denv
infect
diseas
sever
mous
model
zellweg
et
al
anoth
studi
use
mice
matern
acquir
antidenv
antibodi
found
enhanc
viremia
vascular
leakag
lead
earlier
death
ng
et
al
ultim
verif
denvad
human
provid
recent
longterm
pediatr
cohort
studi
dengueendem
nicaragua
studi
observ
highest
risk
sever
dengu
among
individu
suboptim
antidenv
antibodi
titer
protect
symptomat
dengu
high
antibodi
titer
thu
prove
level
preexist
antidenv
antibodi
directli
associ
sever
secondari
dengu
diseas
human
studi
use
monoclon
antibodi
obtain
primarysecondari
dengu
patient
identifi
denv
surfac
protein
e
prm
major
target
host
immun
respons
serafin
aaskov
crill
chang
beltramello
et
al
matsui
et
al
wahala
silva
fibriansah
et
al
gan
et
al
studi
suggest
highli
neutral
antibodi
predominantli
rais
complex
quaternari
epitop
viral
envelop
ediii
later
ridg
region
involv
cellular
attach
antibodi
mostli
serotypespecif
howev
antibodi
rais
quaternari
envelop
dimer
epitop
ede
found
potent
neutral
four
denv
serotyp
dejnirattisai
et
al
protect
antibodi
repres
small
subset
antibodi
repertoir
dengu
patient
immun
respons
domin
crossreact
nonneutr
antibodi
target
edi
edii
fusion
loop
prm
potenti
enhanc
viral
infect
smith
et
al
moreov
neutral
antibodi
also
capabl
enhanc
infect
present
subneutr
concentr
role
antibodi
prm
protein
particularli
import
abil
enhanc
infect
immatur
virion
otherwis
noninfecti
prm
protein
present
intracellular
immatur
viru
particl
cover
fusion
domain
e
protein
thu
prevent
fusion
host
cell
membran
cleavag
precursor
pr
peptid
prm
protein
process
viru
matur
render
releas
matur
viru
particl
infecti
host
cell
round
replic
li
et
al
junjhon
et
al
ineffici
process
prm
protein
result
product
immatur
partial
immatur
viru
particl
normal
noninfecti
due
inabl
fuse
host
cell
howev
studi
use
human
monoclon
antibodi
obtain
person
secondari
dengu
reveal
immatur
viru
particl
capabl
infect
host
cell
presenc
nonneutr
antiprm
antibodi
thu
infecti
secondari
infect
possibl
contribut
sever
diseas
dejnirattisai
et
al
schmidt
similarli
antibodi
specif
fusion
loop
fl
edii
also
shown
enhanc
infect
immatur
denv
particl
rodenhuiszybert
et
al
receptor
present
surfac
cell
myeloid
lineag
function
intern
antibodyopson
viru
via
receptormedi
endocytosi
phagocytosi
thu
aid
clearanc
viru
blood
circul
howev
also
contribut
ade
denv
infect
offer
viru
altern
pathway
entri
target
cell
monocyt
macrophag
dendrit
cell
taylor
et
al
gan
et
al
three
class
human
name
highaffin
activ
receptor
bind
monomer
igg
molecul
vogelpoel
et
al
class
lowaffin
receptor
requir
high
avid
bind
igg
immun
complex
activ
receptor
inhibitori
receptor
guilliam
et
al
activ
receptor
involv
intracellular
signal
transduct
via
immunoreceptor
tyrosinebas
activ
motif
itam
either
accessori
present
within
receptor
cytoplasm
domain
inhibitori
receptor
contain
immunoreceptor
tyrosinebas
inhibitori
motif
itim
cytoplasm
domain
boonnak
et
al
activ
receptor
effici
intern
antibodyopson
viru
involv
neutral
enhanc
depend
antibodi
concentr
receptor
properti
highaffin
receptor
requir
significantli
less
antibodi
complet
neutral
thu
play
predomin
role
denv
neutral
chawla
et
al
contrast
shown
effect
mediat
ade
itamcontain
cytoplasm
tail
play
crucial
role
boonnak
et
al
monocyt
major
site
denv
infect
replic
express
high
level
intermedi
level
express
monocyt
popul
littl
impact
denv
neutral
enhanc
van
de
winkel
anderson
macrophag
express
dendrit
cell
express
decreas
matur
guilliam
et
al
cell
mononuclear
phagocyt
lineag
like
monocyt
macrophag
dendrit
cell
main
target
denv
infect
human
attach
denv
e
protein
ediii
put
cell
surfac
receptor
heparan
sulfat
ctype
lectin
heat
shock
protein
phosphatidylserin
receptor
constitut
first
step
viral
infect
castilla
et
al
cruzoliveira
et
al
follow
penetr
host
cell
receptordepend
clathrinand
dynaminmedi
endocyt
pathway
acid
ph
endocyt
vesicl
trigger
fusion
viral
envelop
endosom
membran
thu
facilit
virion
uncoat
releas
viral
genom
cellular
cytoplasm
ade
antibodyopson
denv
bind
present
surfac
target
cell
intern
endocytosisphagocytosi
entri
pathway
similar
free
viru
howev
show
slight
alter
depend
cell
type
well
engag
vitro
studi
monocyt
cell
line
shown
entri
occur
clathrinco
vesicl
entri
clathrinindepend
also
transloc
lipid
raft
upon
immun
complex
bind
entri
via
receptor
affect
membran
cholesterol
content
carro
et
al
macrophagelik
cell
antibodyopson
viru
shown
intern
phagocyt
uptak
facilit
actinmedi
membran
protrus
activ
search
captur
antibodybound
viru
particl
possibl
chemotaxi
ayalanunez
et
al
addit
primari
cell
receptor
may
also
requir
cell
penetr
fact
one
theori
suggest
play
auxiliari
role
concentr
immun
complex
cell
surfac
viral
entri
mediat
primari
cellular
receptor
chotiwan
et
al
suppress
host
antivir
immun
respons
facilit
higher
viru
product
ade
denv
infect
first
suggest
studi
monocyt
cell
reveal
upregul
antiinflammatori
cytokin
product
downregul
antidenv
free
radic
nitric
oxid
proinflammatori
cytokin
product
chareonsirisuthigul
et
al
subsequ
studi
cell
offer
insight
mechan
intrins
denvad
modhiran
et
al
tsai
et
al
chan
et
al
overal
studi
suggest
type
interferon
proinflammatori
cytokin
product
main
target
immun
suppress
denvad
four
mechan
propos
leukocyt
immunoglobulinlik
receptor
colig
consequ
inhibit
type
interferonstimul
gene
isg
express
downregul
tolllik
receptor
tlr
depend
antivir
signal
pathway
downregul
retino
acidinduc
gene
rigi
melanoma
differentiationassoci
antigen
signal
pathway
result
suppress
type
interferon
ifn
product
induct
product
result
suppressor
cytokin
signal
mediat
suppress
proinflammatori
cytokin
import
antivir
respons
bind
immun
complex
cellular
activ
known
trigger
itamspleen
tyrosin
kinas
syk
signal
transduc
activ
transcript
signal
pathway
lead
isg
induct
inhibit
viral
replic
inhibit
isg
transcript
thu
crucial
success
denv
replic
propos
brought
colig
antibodyopson
denv
chan
et
al
nimmerjahn
lux
belong
famili
itimcontain
inhibitori
receptor
express
immun
effector
cell
includ
monocyt
macrophag
dendrit
cell
subneutr
antibodi
concentr
denvantibodi
immun
complex
bind
two
cellular
receptor
antibodi
denv
e
protein
bind
recruit
src
homolog
dephosphoryl
inactiv
syk
prevent
isg
express
signal
also
prevent
rapid
acidif
lysosom
degrad
denv
ong
et
al
contrari
high
antibodi
concentr
denv
e
protein
epitop
complet
block
antibodi
consequ
bind
possibl
result
neutral
viru
tlrdepend
pathway
key
mediat
innat
antivir
immun
respons
stimul
product
type
ifn
proinflammatori
cytokin
via
nuclear
famili
transcript
factor
studi
use
monocyt
cell
line
patient
peripher
blood
mononuclear
cell
pbmc
shown
pathway
suppress
denvad
engag
fcr
denvantibodi
immun
complex
fcrmediat
entri
immun
complex
target
cell
result
downregul
express
tlr
signal
molecul
accompani
activ
sterilealpha
armadillo
motifcontain
protein
sarm
traf
famili
memberassoci
activ
tank
neg
regul
tlr
adaptor
molecul
tirdomaincontain
adapterinduc
trif
effector
molecul
tnf
receptorassoci
factor
respect
sarmtank
activ
thu
result
suppress
tlrdepend
ifn
stimul
pathway
antivir
signal
pathway
also
downregul
denvad
demonstr
vitro
observ
among
patient
sever
secondari
denv
infect
entri
immun
complex
target
cell
activ
neg
regul
dihydroxyaceton
kinas
dak
autophagyrel
disrupt
signal
cascad
result
suppress
type
ifn
product
ifnmedi
antivir
respons
known
induc
thelper
cell
cytokin
respons
inhibit
product
proinflammatori
cytokin
well
nitric
oxid
radic
potent
inhibitor
denv
replic
induct
denvad
thu
exert
immunosuppress
effect
favor
viral
replic
inde
high
level
associ
sever
diseas
secondari
dengu
patient
ubol
et
al
mechan
immun
suppress
demonstr
vitro
studi
monocyt
cell
line
patient
pbmc
studi
shown
induct
ade
occur
enhanc
sykregul
phosphoinositid
protein
kinas
b
pkb
glycogen
synthas
kinas
gsk
adenosin
monophosph
respons
elementbind
creb
signal
tsai
et
al
stimul
express
subsequ
inactiv
janu
kinas
jak
stat
signal
result
suppress
proinflammatori
cytokin
product
addit
also
suppress
induc
nitric
oxid
synthas
ino
gene
express
thu
nitric
oxid
product
inhibit
interferon
regulatori
factor
activ
chareonsirisuthigul
et
al
ubol
et
al
major
studi
elucid
mechan
intrins
ade
carri
monocyt
cell
line
experi
use
primari
monocytederiv
human
macrophag
demonstr
lower
higher
level
denvad
consist
observ
monocyt
cell
rolph
et
al
howev
induct
downregul
observ
thu
propos
critic
regul
denvad
macrophag
respons
suppress
proinflammatori
cytokin
indic
mechan
intrins
ade
may
cell
typedepend
contradictori
wellaccept
mechan
ademedi
immun
suppress
recent
studi
observ
entri
denv
immun
complex
primari
human
macrophag
trigger
immunosuppress
signal
result
enhanc
fusion
viral
envelop
host
cell
membran
investig
differ
mechan
involv
ade
denv
infect
thu
warrant
extrins
intrins
mechan
ade
togeth
contribut
enhanc
viral
replic
consequ
higher
viremia
level
correl
incid
sever
dengu
patient
vaughn
et
al
ade
also
associ
trigger
cytokin
storm
involv
massiv
releas
inflammatori
cytokin
chemic
mediat
high
level
pang
et
al
ade
denv
infect
replic
result
increas
present
viral
antigen
surfac
infect
cell
lead
activ
prolifer
cell
sensit
prior
infect
result
releas
cytokin
immunoregul
directli
act
upon
vascular
endotheli
cell
result
plasma
leakag
hallmark
sever
dengu
increas
level
cytokin
associ
plasma
leakag
sever
dengu
patient
chaturvedi
et
al
effect
cytokin
respons
alter
vascular
permeabl
demonstr
vitro
mice
model
disrupt
apic
junction
complex
endotheli
cell
suggest
mechan
dewi
et
al
appanna
et
al
puertaguardo
et
al
gener
longterm
protect
immun
respons
four
serotyp
denv
prerequisit
dengu
vaccin
assum
greater
import
due
associ
risk
vaccineinduc
ade
denv
infect
diseas
sixdecad
long
quest
effect
dengu
vaccin
sever
candid
liveattenu
inactiv
recombin
subunit
viruslik
particl
vlp
base
dna
vaccin
explor
sanofi
pasteur
dengvaxia
cydtdv
chimer
yellow
fever
denv
vaccin
nation
institut
health
takeda
pharmaceut
live
attenu
tetraval
vaccin
lead
develop
pipelin
mcarthur
et
al
cydtdv
approv
human
use
licens
countri
current
undergo
phase
iii
trial
cydtdv
world
first
licens
dengu
vaccin
approv
world
health
organ
may
follow
phase
iii
trial
dengueendem
region
caped
et
al
villar
et
al
hadinegoro
et
al
trial
demonstr
high
vaccin
efficaci
among
first
year
vaccin
first
three
dose
administr
indic
increas
risk
hospit
dengu
year
age
group
third
year
followup
result
suggest
possibl
vaccin
sensit
dengu
seroneg
subsequ
enhanc
denv
infect
diseas
howev
consid
populationlevel
benefit
reduc
diseas
burden
vaccin
approv
strateg
advisori
group
expert
sage
immun
recommend
use
dengueendem
region
seropreval
administr
individu
age
rang
year
approv
follow
addit
studi
investig
longterm
benefitrisk
ratio
dengu
vaccin
seroneg
popul
studi
reveal
vaccin
perform
inde
affect
serostatu
vaccin
efficaci
significantli
higher
seroposit
seroneg
furthermor
increas
risk
hospit
sever
dengu
observ
among
seroneg
vaccin
recipi
compar
seroneg
control
sridhar
et
al
light
new
evid
regard
vaccinerel
ade
whosag
issu
updat
recommend
use
cydtdv
vaccin
april
wildersmith
et
al
countri
consid
vaccin
part
dengu
control
program
recommend
prevaccin
screen
strategi
potenti
vaccin
recipi
test
antidenv
igg
prefer
elisa
dengueseroposit
person
vaccin
trial
new
vaccin
advis
stratif
particip
accord
prevaccin
serostatu
data
analysi
well
longterm
followup
vaccin
recipi
occurr
breakthrough
infect
cydtdv
vaccine
despit
high
titer
neutral
antibodi
rais
concern
regard
valu
current
use
vitro
neutral
test
correl
protect
neutral
potenti
antibodi
commonli
evalu
use
plaqu
reduct
neutral
test
prnt
vero
cell
line
howev
neutral
denv
infect
cell
may
reflect
abil
antibodi
prevent
infect
myeloid
cell
primari
target
denv
capabl
intern
antibodyopson
denv
phagocytosi
use
cell
line
primari
myeloid
cell
vitro
neutral
thu
propos
measur
neutral
versu
enhanc
abil
antidenv
antibodi
mahalingam
et
al
gan
et
al
furthermor
identif
stronger
immun
correl
diseas
risk
protect
urgent
need
result
phase
iii
trial
vaccin
await
concern
vaccinerel
ade
promot
develop
vaccin
specif
design
minim
ade
monoclon
antibodybas
studi
help
identifi
neutral
enhanc
viral
epitop
make
design
tailor
vaccin
possibl
denv
ediii
induc
predominantli
neutral
antibodi
thu
make
recombin
ediii
attract
subunit
vaccin
candid
gil
et
al
frei
et
al
denv
also
consid
vaccin
candid
avoid
ade
hertz
et
al
chimer
denv
construct
pr
gene
replac
japanes
enceph
viru
pr
dna
vaccin
substitut
remov
enhanc
epitop
demonstr
reduct
ade
crill
et
al
tang
et
al
wang
et
al
anoth
strategi
evas
ade
develop
vaccin
candid
induc
protect
tcell
respons
denv
c
protein
immunodomin
tcell
epitop
cbase
vaccin
shown
induct
protect
tcellmedi
immun
monkey
gil
et
al
nextgener
vaccin
face
disadvantag
retain
intact
virion
structur
quaternari
epitop
import
potent
neutral
howev
vaccin
shown
encourag
result
preclin
studi
whether
capabl
confer
vivo
protect
remain
seen
human
monoclon
antibodi
mab
attract
therapeut
option
denv
infect
therapeut
mab
must
neutral
denv
without
increas
risk
ade
order
offer
protect
dengu
sever
mab
target
denv
e
andor
prm
protein
develop
therapeut
candid
reduct
ade
major
focu
develop
sun
et
al
use
serotypespecif
mab
high
dose
administr
crossreact
mab
demonstr
reduc
risk
ade
vitro
anim
model
antibodi
modif
fc
region
delet
nine
amino
acid
posit
n
terminu
mutat
asparagin
glutamin
posit
mutat
leucin
alanin
posit
lala
mutant
also
shown
reduc
risk
ade
exhibit
prophylact
therapeut
efficaci
anim
model
balsiti
et
al
shi
et
al
xu
et
al
injampa
et
al
lu
et
al
fc
region
modif
extend
antibodi
halflif
also
help
minim
ade
maintain
mab
high
level
ade
also
report
virus
famili
flavivirida
includ
murray
valley
enceph
viru
japanes
enceph
viru
jev
west
nile
viru
wnv
yellow
fever
viru
yfv
zika
viru
zikv
genu
flaviviru
well
hepat
c
viru
hcv
genu
hepaciviru
hawk
lafferti
cardosa
et
al
gould
buckley
meyer
et
al
bardina
et
al
infect
one
flaviviru
also
demonstr
enhanc
subsequ
infect
anoth
viru
genu
observ
denvzikv
vitro
studi
mice
model
rhesu
macaqu
bardina
et
al
georg
et
al
denvzikv
crossenhanc
also
observ
primari
human
pbmc
li
et
al
howev
absenc
clinic
epidemiolog
evid
clinic
relev
find
unknown
interestingli
benefici
effect
crossenhanc
among
flavivirus
report
recent
clinic
trial
preexist
jev
vaccineinduc
antibodi
enhanc
immunogen
subsequ
administ
yfv
vaccin
human
immunodefici
viru
hiv
member
famili
retrovirida
genu
lentiviru
primarili
sexual
transmit
viru
nonsexu
transmiss
intraven
inocul
mothertochild
exposur
also
occur
hiv
infect
cell
lead
progress
deplet
thu
hamper
host
adapt
immun
respons
final
stage
hiv
infect
acquir
immunodefici
syndrom
aid
character
immun
system
failur
occurr
lifethreaten
opportunist
infect
million
peopl
worldwid
estim
live
hiv
ghosn
et
al
protect
vaccin
complet
cure
hiv
infect
remain
elus
implement
combin
antiretrovir
therapi
cart
success
prolong
durat
hiv
infect
aid
reduc
aidsrel
death
ade
hiv
infect
first
report
shortli
identif
isol
hiv
two
differ
mechan
name
complementmedi
ade
cade
robinson
jr
et
al
fcrmediat
ade
fcrade
takeda
et
al
homsi
et
al
describ
either
mechan
virusspecif
antibodi
present
sera
hivinfect
individu
shown
enhanc
viral
entri
case
replic
within
cell
monocytesmacrophag
granulocyt
cell
beck
et
al
mechan
also
shown
enhanc
hiv
infect
human
syncytiotrophoblast
cell
thu
suggest
contribut
ade
maternofet
transmiss
et
al
form
ade
mediat
antibodi
target
viral
surfac
glycoprotein
trischmann
et
al
enhanc
antibodi
detect
hiv
patient
subbramanian
et
al
cade
hiv
infect
well
character
vitro
studi
tcell
line
show
enhanc
cell
lineadapt
hiv
strain
primari
viru
isol
human
monoclon
antibodi
sera
hivinfect
individu
associ
increas
synthesi
viral
rna
protein
enhanc
releas
infecti
virion
robinson
jr
et
al
robinson
jr
willey
et
al
cade
primarili
mediat
antibodi
target
ntermin
immunodomin
domain
viral
antibodi
bind
initi
complement
cascad
lead
deposit
complement
compon
g
virion
interact
opson
viru
cell
surfac
complement
receptor
type
facilit
viru
attach
intern
engag
hiv
receptor
coreceptor
also
requir
mode
viru
uptak
increas
attach
viru
target
cell
rather
signal
suggest
respons
enhanc
infect
cade
altern
rout
complement
compon
bind
follow
interact
receptor
also
suggest
cade
prohaszka
et
al
fcrade
demonstr
vitro
mainli
monocytemacrophag
cell
line
primari
cultur
three
class
name
report
support
ade
homsi
et
al
takeda
et
al
takeda
et
al
laurenc
et
al
connor
et
al
trischmann
et
al
ade
requir
viral
interact
indic
fcr
facilit
viru
entri
potenti
attach
receptor
altern
fcrmediat
endocytosi
virusantibodi
complex
follow
intracellular
fusion
endosom
membran
occur
result
bind
viru
receptor
endosom
membran
also
suggest
ade
shown
fcrade
assum
particular
import
viral
life
cycl
mediat
infect
macrophag
import
maintain
viral
reservoir
persist
infect
anoth
mechan
complementindepend
fcrindepend
ade
mediat
antibodi
specif
viral
describ
sullivan
et
al
guillon
et
al
antibodi
bind
shown
modul
interact
hiv
coreceptor
induc
conform
chang
lead
activ
subsequ
promot
membran
fusion
ade
also
report
human
serum
iga
show
lowlevel
enhanc
hiv
replic
vitro
janoff
et
al
kozlowski
et
al
import
featur
hiv
rapid
viral
evolut
chronic
infect
neutral
antibodi
known
exert
select
pressur
facilit
emerg
neutral
escap
mutant
enhanc
antibodi
suggest
favor
emerg
adesuscept
variant
inde
later
stage
infect
patient
sera
demonstr
increas
proport
enhanc
antibodi
potenti
ade
viru
strain
isol
later
stage
exhibit
increas
suscept
ade
vitro
davi
et
al
subbramanian
et
al
willey
et
al
hiv
diseas
outcom
suggest
influenc
balanc
neutral
enhanc
antibodi
hiv
patient
studi
show
lower
neutral
higher
enhanc
antibodi
level
among
aid
patient
homsi
et
al
toth
et
al
fust
et
al
szabo
et
al
subbramanian
et
al
studi
observ
strong
neg
correl
extent
ade
cell
count
posit
correl
ade
plasma
viral
load
hivposit
individu
cell
count
hiv
plasma
viral
load
consid
potent
predictor
hiv
diseas
progress
observ
indic
contribut
ade
acceler
immunosuppress
diseas
progress
support
associ
provid
report
declin
enhanc
antibodi
level
improv
diseas
prognosi
patient
receiv
highli
activ
antiretrovir
therapi
haart
banhegyi
et
al
contradictori
observ
absenc
clinic
correl
ade
diseas
also
report
montefiori
et
al
howev
suggest
result
conduct
experi
condit
suffici
resembl
vivo
condit
beck
et
al
impact
ade
hiv
vaccin
safeti
clearli
understood
studi
rhesu
monkey
demonstr
associ
activ
passiv
immun
enhanc
diseas
progress
subsequ
infect
stapran
et
al
sholukh
et
al
human
ade
indic
two
vaccin
clinic
trial
aidsvax
trial
rate
hiv
infect
observ
higher
among
vaccine
low
nonprotect
antibodi
respons
gilbert
et
al
trial
posit
correl
vaccineelicit
plasma
iga
respons
risk
hiv
acquisit
document
shmelkov
et
al
studi
investig
effect
passiv
immun
hivposit
pregnant
women
mothertoinf
transmiss
suggest
possibl
antibodyenhanc
utero
transmiss
onyangomakumbi
et
al
find
suggest
vaccineinduc
ade
confirm
assay
capabl
estim
neutral
enhanc
potenti
immun
serum
involv
use
complement
complement
receptor
carri
target
cell
cade
propos
better
understand
clinic
relev
vaccinerel
ade
assay
would
also
provid
stronger
immun
correl
preclin
clinic
studi
design
vaccin
immunogen
elicit
protect
enhanc
antibodi
avoid
inclus
known
enhanc
epitop
put
forth
mitig
strategi
hivad
beck
et
al
influenza
highli
communic
acut
respiratori
diseas
caus
infect
influenza
viru
famili
orthomyxovirida
diseas
seriou
health
threat
epidem
pandem
proport
sever
case
associ
pneumonia
lung
tissu
damag
influenza
virus
common
human
infect
classifi
subtyp
basi
two
surfac
protein
hemagglutinin
h
neuraminidas
n
h
n
subtyp
identifi
shao
et
al
influenza
viru
undergo
rapid
evolut
due
mechan
antigen
drift
shift
genet
reassort
result
period
emerg
novel
viral
strain
annual
vaccin
circul
viral
strain
thu
implement
protect
diseas
epitheli
cell
respiratori
tract
primari
target
influenza
viru
infect
howev
vitro
ade
viru
report
primari
macrophag
macrophagelik
cell
line
presenc
monoclon
antibodi
mice
rabbit
human
immun
sera
ochiai
et
al
ochiai
et
al
ochiai
et
al
tamura
et
al
tamura
et
al
gotoff
et
al
engag
antibodi
specif
viral
ha
na
shown
mediat
viru
uptak
subtyp
crossreact
nonneutr
antibodi
particularli
involv
infect
enhanc
heterotyp
virus
differ
hana
type
intern
usual
result
abort
infect
macrophag
product
replic
cell
shown
possibl
presenc
appropri
proteas
ha
cleavag
increas
present
viral
antigen
infect
macrophag
lead
augment
virusspecif
tcell
activ
also
suggest
contribut
viral
pathogenesi
enhanc
viru
fusion
subunit
antibodi
anoth
mechan
influenzaad
shown
respons
occurr
vaccineassoci
enhanc
respiratori
diseas
vaerd
pig
immun
inactiv
vaccin
challeng
pandem
viru
gauger
et
al
khurana
et
al
influenzaad
also
suggest
epidemiolog
observ
human
retrospect
analysi
medic
record
influenza
pandem
reveal
associ
prior
influenzalik
ill
increas
risk
medic
attend
ill
pandem
period
shank
et
al
recent
prior
receipt
season
influenza
vaccin
found
increas
risk
medic
attend
pandem
ill
canada
skowronski
et
al
furthermor
presenc
high
titer
nonprotect
serum
antibodi
associ
immun
complexmedi
sever
ill
pandem
monsalvo
et
al
et
al
observ
vaerd
pig
ferret
immun
inactiv
ha
subunit
vaccin
rais
concern
regard
safeti
vaccin
particularli
univers
influenza
vaccin
gauger
et
al
khurana
et
al
rajao
et
al
skowronski
et
al
howev
vaccinemedi
protect
absenc
vaerd
also
report
studi
pig
suggest
vaccineinduc
ade
occur
certain
condit
yet
clearli
understood
reeth
et
al
kyriaki
et
al
ricklin
et
al
regard
therapeut
candid
phase
studi
antiha
stalk
mab
indic
possibl
enhanc
viral
shed
treat
human
subject
screen
high
potenc
protect
antibodi
defin
optim
dose
rang
effect
neutral
use
cocktail
mab
differ
antigen
specif
suggest
mitig
ade
chanhui
swiderek
respiratori
syncyti
viru
rsv
member
famili
paramyxovirida
genu
pneumoviru
lead
caus
lower
respiratori
tract
infect
among
infant
young
children
worldwid
sever
diseas
requir
hospit
occur
frequent
week
month
life
glezen
et
al
hall
et
al
rsv
diseas
also
major
health
problem
adult
elderli
sever
bronchiol
one
major
outcom
rsv
infect
observ
enhanc
diseas
among
children
receiv
formalininactiv
rsv
firsv
vaccin
kim
et
al
well
frequent
occurr
sever
diseas
among
infant
month
age
matern
antibodi
present
prompt
investig
ade
rsv
infect
subsequ
enhanc
rsv
infect
rsvspecif
monoclon
antibodi
human
immun
sera
demonstr
vitro
monocyt
macrophagelik
cell
line
gimenez
et
al
gimenez
et
al
krilov
et
al
osiowi
et
al
phenomenon
also
report
bonnet
monkey
develop
enhanc
diseas
follow
firsv
immun
ponnuraj
et
al
ponnuraj
et
al
intern
immun
complex
suggest
mechan
antibodi
viral
surfac
glycoprotein
attach
glycoprotein
g
fusion
glycoprotein
f
play
import
role
although
epitheli
cell
respiratori
tract
primari
target
rsv
infect
suggest
alveolar
macrophag
infect
ade
result
activ
respons
increas
express
thu
caus
enhanc
diseas
gimenez
et
al
ademedi
infect
lung
dendrit
cell
dc
demonstr
neg
modul
dc
cell
function
result
impair
tcell
activ
suggest
contribut
rsv
pathogenesi
gomez
et
al
howev
clinic
effect
rsvade
still
remain
unclear
differ
studi
report
contradictori
observ
regard
associ
matern
antibodyinduc
ade
diseas
sever
infant
chanock
et
al
van
erp
et
al
enhanc
rsv
diseas
firsv
vaccin
recipi
initi
attribut
vaccineinduc
ade
howev
recent
studi
suggest
role
mechan
involv
cell
huisman
et
al
whether
ade
would
affect
efficaci
rsv
vaccin
develop
remain
seen
far
immunotherapeut
concern
f
proteinspecif
human
monoclon
antibodi
palivizumab
clinic
approv
intervent
mab
demonstr
ade
subneutr
concentr
vitro
yet
found
protect
effect
anim
model
human
ti
rs
group
et
al
van
mechelen
et
al
ebola
viru
member
famili
filovirida
four
ebola
viru
speci
infect
human
zair
ebolaviru
ebov
virul
caus
agent
sever
hemorrhag
fever
diseas
ebola
viru
diseas
evd
fatal
rate
feldmann
geisbert
diseas
zoonot
initi
case
occur
due
contact
infect
fruit
bat
reservoir
contamin
materi
follow
humantohuman
transmiss
viru
mainli
endem
africa
howev
due
increas
incid
fast
spread
observ
african
outbreak
viru
consid
pandem
threat
ade
ebola
viru
infect
demonstr
vitro
varieti
cell
line
shown
mediat
antibodi
specif
viral
envelop
glycoprotein
gp
takada
et
al
takada
et
al
enhanc
antibodi
identifi
sera
evd
patient
furuyama
et
al
two
differ
mechan
propos
ade
ebov
infect
ade
b
ade
ade
antibodyviru
complex
bind
cell
surfac
trigger
phosphoryl
src
famili
protein
tyrosin
kinas
ptk
activ
src
signal
pathway
lead
viru
uptak
phagocytosi
andor
micropinocytosi
furuyama
et
al
ade
involv
interact
virusbound
antibodi
complement
compon
subsequ
attach
cell
surfac
receptor
lead
viru
intern
receptormedi
endocytosi
via
virusspecif
receptor
takada
et
al
receptor
present
monocytesmacrophag
primari
target
ebov
well
mammalian
cell
includ
endotheli
cell
epitheli
cell
hepatocyt
mediat
dissemin
ebov
infect
secondari
target
cell
suggest
exacerb
diseas
although
clinic
relev
ebovad
yet
understood
repeat
vitro
demonstr
rais
concern
regard
safeti
vaccin
immunotherapeut
sever
candid
vaccin
develop
demonstr
protect
efficaci
preclin
studi
immunogen
clinic
trial
dhama
et
al
protect
effect
vaccin
seem
depend
cytotox
tcell
respons
avoid
induct
known
infectivityenhanc
antibodi
retain
tcell
epitop
thu
consid
vaccin
design
immunotherapi
use
wellcharacter
mab
instead
polyclon
convalesc
human
serum
suggest
reduc
ade
sever
acut
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
sar
respiratori
diseas
caus
sarscoronaviru
sarscov
famili
coronavirida
caus
outbreak
mainli
china
china
although
public
health
measur
success
contain
spread
human
outbreak
futur
reemerg
sarscov
relat
virus
remain
credibl
threat
due
zoonot
origin
viru
ade
sarscov
infect
first
demonstr
vitro
human
b
cell
use
sera
immun
anim
well
convalesc
patient
kam
et
al
studi
show
antibodi
specif
viral
surfac
spike
glycoprotein
capabl
enhanc
viral
infect
immun
cell
particularli
monocyt
macrophag
thu
allow
viru
broaden
cellular
tropism
jaum
et
al
wang
et
al
yip
et
al
intern
immun
complex
cellular
mainli
suggest
mechan
intracellular
signal
cytosol
domain
play
import
role
intern
follow
phand
cystein
proteaseindepend
pathway
differ
endosomallysosom
pathway
util
angiotensin
iconvert
enzym
accept
receptor
sarscov
antibodymedi
infect
macrophag
howev
found
support
product
viru
replic
modifi
express
cytokin
chemokin
yip
et
al
although
demonstr
recent
rhesu
monkey
occurr
sarsad
associ
diseas
sever
human
still
debat
differ
clinic
studi
report
protect
diseaseenhanc
effect
antisarscov
antibodi
lee
et
al
zhang
et
al
chikungunya
viru
chikv
arboviru
belong
famili
togavirida
genu
alphaviru
viru
recogn
signific
global
health
threat
sinc
last
decad
primarili
transmit
bite
infect
aed
mosquito
aed
aegypti
aed
albopictu
chikv
infect
associ
febril
ill
accompani
myalgia
arthralgia
cutan
rash
kam
et
al
debilit
persist
polyarthralgia
characterist
featur
chikungunya
diseas
ade
chikv
infect
suggest
associ
low
titer
antichikv
igg
immun
mice
earli
onset
diseas
upon
subsequ
chikv
challeng
hallengard
et
al
anoth
recent
studi
observ
enhanc
attach
chikv
primari
human
monocyt
b
cell
increas
viral
replic
murin
macrophag
cell
line
presenc
antichikv
antibodi
lum
et
al
studi
also
detect
higher
viral
rna
load
enhanc
diseas
sever
mice
infect
chikv
presenc
subneutr
concentr
antibodi
thu
provid
first
evid
ade
chikv
infect
diseas
enhanc
found
play
predomin
role
howev
ade
chikv
infect
report
date
human
thu
clinic
signific
find
remain
unknown
warrant
investig
virusspecif
antibodi
function
neutral
viru
infect
import
compon
host
antivir
immun
respons
howev
subneutr
nonneutr
condit
antibodi
capabl
enhanc
viral
infect
provid
altern
rout
viru
entri
host
cell
phenomenon
antibodydepend
enhanc
facilit
viral
infect
larger
number
primari
target
cell
also
allow
viral
entri
otherwis
nonsuscept
secondari
target
cell
thu
broaden
viru
tropism
moreov
ade
also
modul
host
intracellular
signal
pathway
therebi
turn
antivir
immun
respons
togeth
mechan
serv
augment
viral
replic
pathogenesi
balanc
neutral
enhanc
antibodi
influenc
outcom
viral
infect
diseas
ade
demonstr
vitro
anim
model
number
virus
includ
denv
hiv
influenza
rsv
ebola
sarscov
chikv
occurr
denvad
human
associ
sever
diseas
clearli
demonstr
clinic
relev
ade
virus
complet
understood
nevertheless
ade
remain
concern
develop
use
vaccin
immunotherapeut
virus
recent
advanc
identif
neutral
enhanc
viral
epitop
expect
guid
futur
design
nonenhanc
protect
viral
vaccin
therapeut
mab
comprehens
evalu
humor
cellmedi
immun
respons
vaccin
preclin
clinic
studi
help
robust
assay
detect
ade
suggest
crucial
assess
vaccin
safeti
efficaci
evalu
would
requir
better
understand
immun
correl
protect
lastli
investig
longterm
effect
vaccin
implement
advis
consid
approv
futur
vaccin
